{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:49:55Z","timestamp":1787071795144,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctrv.2026.103136","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:48:25Z","timestamp":1776066505000},"page":"103136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Multigene assays in early breast cancer: Current evidence, limits and future directions"],"prefix":"10.1016","volume":"146","author":[{"given":"Emanuela","family":"Fina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Di","family":"Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Colomba","family":"Comes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele De","family":"Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103136_b0005","doi-asserted-by":"crossref","unstructured":"Beca F, Polyak K. Intratumor Heterogeneity in Breast Cancer. Adv Exp Med Biol. 2016;882:169-89. doi: 10.1007\/978-3-319-22909-6_7. PMID: 26987535.2. Weigelt B. J Pathol. 2008 Oct;216(2):141-50. doi: 10.1002\/path.2407.","DOI":"10.1002\/path.2407"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103136_b0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.2407","article-title":"Refinement of breast cancer classification by molecular characterization of histological special types","volume":"216","author":"Weigelt","year":"2008","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103136_b0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-031-70875-6_9","article-title":"Cells-of-Origin of Breast Cancer and Intertumoral Heterogeneity","volume":"1464","author":"Joyce","year":"2025","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0025","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103136_b0030","doi-asserted-by":"crossref","unstructured":"Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200\/JCO.2015.65.2289. Epub 2016 Feb 8. PMID: 26858339; PMCID: PMC4933134.","DOI":"10.1200\/JCO.2015.65.2289"},{"key":"10.1016\/j.ctrv.2026.103136_b0035","doi-asserted-by":"crossref","unstructured":"Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 Jun 1;40(16):1816-1837. doi: 10.1200\/JCO.22.00069. Epub 2022 Apr 19. Erratum in: J Clin Oncol. 2022 Aug 1;40(22):2514. doi: 10.1200\/JCO.22.01388. PMID: 35439025.","DOI":"10.1200\/JCO.22.00069"},{"key":"10.1016\/j.ctrv.2026.103136_b0040","doi-asserted-by":"crossref","unstructured":"K. Halabi S, Owzar K. The importance of identifying and validating prognostic factors in oncology. Semin Oncol. 2010 Apr;37(2):e9-18. doi: 10.1053\/j.seminoncol.2010.04.001. PMID: 20494694; PMCID: PMC2929829.","DOI":"10.1053\/j.seminoncol.2010.04.001"},{"key":"10.1016\/j.ctrv.2026.103136_b0045","doi-asserted-by":"crossref","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093\/annonc\/mdv221. Epub 2015 May 4. PMID: 25939896; PMCID: PMC4511219.","DOI":"10.1093\/annonc\/mdv221"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103136_b0050","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","article-title":"Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer","volume":"19","author":"Ravdin","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103136_b0055","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.2005.06.178","article-title":"Population-based validation of the prognostic model ADJUVANT! for early breast cancer","volume":"23","author":"Olivotto","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0060","doi-asserted-by":"crossref","unstructured":"Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylk\u00e4s K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, B\u00e9gin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012 Aug 21;107(5):800-7. doi: 10.1038\/bjc.2012.338. Epub 2012 Jul 31. PMID: 22850554; PMCID: PMC3425970.","DOI":"10.1038\/bjc.2012.338"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103136_b0065","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrclinonc.2010.170","article-title":"Breast cancer assessment tools and optimizing adjuvant therapy","volume":"7","author":"Oakman","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103136_b0070","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ctrv.2026.103136_b0080","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103136_b0085","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1186\/bcr1798","article-title":"International Web-based consultation on priorities for translational breast cancer research","volume":"9","author":"Dowsett","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM198902233200803","article-title":"Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study","volume":"320","author":"Mansour","year":"1989","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103136_b0095","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103136_b0100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2007.15.1068","article-title":"Development of the 21-gene assay and its application in clinical practice and clinical trials","volume":"26","author":"Sparano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0105","doi-asserted-by":"crossref","unstructured":"Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200\/JCO.2007.14.4501. Epub 2008 Aug 4. Erratum in: J Clin Oncol. 2009 Jul 20;27(21):3566. PMID: 18678838; PMCID: PMC2654377.","DOI":"10.1200\/JCO.2007.14.4501"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103136_b0110","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0115","doi-asserted-by":"crossref","unstructured":"Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200\/JCO.2009.23.7610. Epub 2010 Jan 11. PMID: 20065188; PMCID: PMC2849763.","DOI":"10.1200\/JCO.2009.23.7610"},{"key":"10.1016\/j.ctrv.2026.103136_b0120","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056\/NEJMoa1510764. Epub 2015 Sep 27. PMID: 26412349; PMCID: PMC4701034.","DOI":"10.1056\/NEJMoa1510764"},{"key":"10.1016\/j.ctrv.2026.103136_b0125","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056\/NEJMoa1804710. Epub 2018 Jun 3. PMID: 29860917; PMCID: PMC6172658.","DOI":"10.1056\/NEJMoa1804710"},{"key":"10.1016\/j.ctrv.2026.103136_b0130","doi-asserted-by":"crossref","unstructured":"Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson Jr, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge. Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS1-05.","DOI":"10.1158\/1538-7445.SABCS22-GS1-05"},{"key":"10.1016\/j.ctrv.2026.103136_b0135","doi-asserted-by":"crossref","unstructured":"Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016\/S1470-2045(09)70314-6. Epub 2009 Dec 10. PMID: 20005174; PMCID: PMC3058239.","DOI":"10.1016\/S1470-2045(09)70314-6"},{"key":"10.1016\/j.ctrv.2026.103136_b0140","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056\/NEJMoa2108873. Epub 2021 Dec 1. PMID: 34914339; PMCID: PMC9096864.","DOI":"10.1056\/NEJMoa2108873"},{"key":"10.1016\/j.ctrv.2026.103136_b0145","doi-asserted-by":"crossref","unstructured":"Sparano JA, Crager M, Gray RJ, Tang G, Hoag J, Baehner FL, Shak S, Makower DF, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Whelan TJ, Kaklamani VG, Wolmark N, Sledge GW, Stemmer SM. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival. NEJM Evid. 2024 Aug;3(8):EVIDoa2300267. doi: 10.1056\/EVIDoa2300267. Epub 2024 Jul 23. PMID: 39041867; PMCID: PMC11730053.","DOI":"10.1056\/EVIDoa2300267"},{"key":"10.1016\/j.ctrv.2026.103136_b0150","doi-asserted-by":"crossref","unstructured":"LHRH-agonists in Early Breast Cancer Overview group; Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016\/S0140-6736(07)60778-8. PMID: 17512856.","DOI":"10.1016\/S0140-6736(07)60778-8"},{"key":"10.1016\/j.ctrv.2026.103136_b0155","doi-asserted-by":"crossref","unstructured":"Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, L\u00e1ng I, G\u00f3mez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM; SOFT and TEXT Investigators and International Breast Cancer Study Group. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 Apr 20;38(12):1293-1303. doi: 10.1200\/JCO.18.01967. Epub 2019 Oct 16. PMID: 31618131; PMCID: PMC7164485.","DOI":"10.1200\/JCO.18.01967"},{"key":"10.1016\/j.ctrv.2026.103136_b0160","doi-asserted-by":"crossref","unstructured":"Sandra M. Swain et al. INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).. J Clin Oncol 42, TPS1124-TPS1124(2024). DOI:10.1200\/JCO.2024.42.16_suppl.TPS1124.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1124"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103136_b0165","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jnci\/djae314","article-title":"Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial","volume":"117","author":"Abdou","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103136_b0170","doi-asserted-by":"crossref","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016\/S0140-6736(13)62422-8. Epub 2014 Feb 14. Erratum in: Lancet. 2019 Mar 9;393(10175):986. doi: 10.1016\/S0140-6736(18)32772-7. PMID: 24529560.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"10.1016\/j.ctrv.2026.103136_b0175","doi-asserted-by":"crossref","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. doi: 10.1158\/1078-0432.CCR-19-3492. Epub 2020 Feb 11. PMID: 32046998; PMCID: PMC7299787.","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103136_b0180","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1200\/JCO.2005.02.0818","article-title":"Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer","volume":"23","author":"Gianni","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103136_b0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.breast.2009.03.005","article-title":"21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients","volume":"18","author":"Akashi-Tanaka","year":"2009","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103136_b0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10147-013-0614-x","article-title":"Evaluating the 21-gene assay recurrence score\u00ae as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer","volume":"19","author":"Ueno","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0195","doi-asserted-by":"crossref","unstructured":"Aziza Nassar, Jodi Carter, Paige Innis, Satish Seerapu, Christy Russell, Helena Hanna, Abigail Lochala, Minetta Liu. Concordance analysis of paired breast cancer core needle biopsies and surgical excision samples using the Oncotype DX Breast Recurrence Score\u00ae assay [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO4-08-09.","DOI":"10.1158\/1538-7445.SABCS23-PO4-08-09"},{"key":"10.1016\/j.ctrv.2026.103136_b0200","doi-asserted-by":"crossref","unstructured":"Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019 Jan;173(1):123-133. doi: 10.1007\/s10549-018-4964-y. Epub 2018 Sep 21. PMID: 30242578; PMCID: PMC6394785.","DOI":"10.1007\/s10549-018-4964-y"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103136_b0205","article-title":"The run-in phase of the prospective WSG-ADAPT HR+\/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer","volume":"23","author":"Nitz","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103136_b0210","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+\/HER2- Early Breast Cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0215","doi-asserted-by":"crossref","unstructured":"Amelia Bruce Zelnak et al. Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer.. J Clin Oncol 31, 562-562(2013). DOI:10.1200\/jco.2013.31.15_suppl.562.","DOI":"10.1200\/jco.2013.31.15_suppl.562"},{"key":"10.1016\/j.ctrv.2026.103136_b0220","doi-asserted-by":"crossref","unstructured":"Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. J Surg Oncol. 2017 Jun;115(8):917-923. doi: 10.1002\/jso.24610. Epub 2017 Apr 13. Erratum in: J Surg Oncol. 2018 Sep;118(4):722. doi: 10.1002\/jso.24798. Erratum in: J Surg Oncol. 2021 Oct;124(5):914. doi: 10.1002\/jso.26625. PMID: 28407247; PMCID: PMC5481477.","DOI":"10.1002\/jso.26625"},{"key":"10.1016\/j.ctrv.2026.103136_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102887","article-title":"Current controversies in the use of Oncotype DX in early breast cancer","volume":"135","author":"Berton Giachetti","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103136_b0230","doi-asserted-by":"crossref","unstructured":"van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002 Jan 31;415(6871):530-6. doi: 10.1038\/415530a. PMID: 11823860.","DOI":"10.1038\/415530a"},{"key":"10.1016\/j.ctrv.2026.103136_b0235","doi-asserted-by":"crossref","unstructured":"van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056\/NEJMoa021967. PMID: 12490681.","DOI":"10.1056\/NEJMoa021967"},{"key":"10.1016\/j.ctrv.2026.103136_b0240","doi-asserted-by":"crossref","unstructured":"Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92. doi: 10.1093\/jnci\/djj329. PMID: 16954471.","DOI":"10.1093\/jnci\/djj329"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103136_b0245","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2007.14.3222","article-title":"Clinical application of the 70-gene profile: the MINDACT trial","volume":"26","author":"Cardoso","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103136_b0250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncponc0591","article-title":"TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial","volume":"3","author":"Bogaerts","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0255","doi-asserted-by":"crossref","unstructured":"Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056\/NEJMoa1602253. PMID: 27557300.","DOI":"10.1056\/NEJMoa1602253"},{"key":"10.1016\/j.ctrv.2026.103136_b0260","doi-asserted-by":"crossref","unstructured":"Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van 't Veer LJ. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010 Apr;21(4):717-722. doi: 10.1093\/annonc\/mdp388. Epub 2009 Oct 13. PMID: 19825882.","DOI":"10.1093\/annonc\/mdp388"},{"key":"10.1016\/j.ctrv.2026.103136_b0265","doi-asserted-by":"crossref","unstructured":"Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, K\u00fcmmel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021 Apr;22(4):476-488. doi: 10.1016\/S1470-2045(21)00007-3. Epub 2021 Mar 12. PMID: 33721561.","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"10.1016\/j.ctrv.2026.103136_b0270","doi-asserted-by":"crossref","unstructured":"Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016\/S1470-2045(07)70346-7. Epub 2007 Nov 26. Erratum in: Lancet Oncol. 2008 Jan;9(1):10. PMID: 18042430.","DOI":"10.1016\/S1470-2045(07)70346-7"},{"key":"10.1016\/j.ctrv.2026.103136_b0275","doi-asserted-by":"crossref","unstructured":"Drukker CA, Bueno-de-Mesquita JM, Ret\u00e8l VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002\/ijc.28082. Epub 2013 Mar 4. PMID: 23371464; PMCID: PMC3734625.","DOI":"10.1002\/ijc.28082"},{"key":"10.1016\/j.ctrv.2026.103136_b0280","doi-asserted-by":"crossref","unstructured":"Brufsky AM, Hoskins KF, Conter HJ, Kelemen P, Habibi M, Samian L, Rahman RL, Lee L, Dias EC, Hampton R, Sieling BA, Osborne CR, Brown E, Elayoubi JA, Sharma P, Ramadurai J, Matt-Amaral L, Santillan AA, Davis S, Albaneze P, Ramaswamy H, Chmielewski-Stivers N, Menicucci A, Audeh W, Whitworth P, Johnson N, O'Shaughnessy J. MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data. JNCI Cancer Spectr. 2025 Sep 1;9(5):pkaf079. doi: 10.1093\/jncics\/pkaf079. PMID: 40796181; PMCID: PMC12413225.","DOI":"10.1093\/jncics\/pkaf079"},{"key":"10.1016\/j.ctrv.2026.103136_b0285","doi-asserted-by":"crossref","unstructured":"Vliek SB, Hilbers FS, Jager A, Ret\u00e8l VP, Bueno de Mesquita JM, Drukker CA, Veltkamp SC, Zeillemaker AM, Rutgers EJ, van Tinteren H, van Harten WH, van 't Veer LJ, van de Vijver MJ, Linn SC. Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. Eur J Cancer. 2022 Nov;175:169-179. doi: 10.1016\/j.ejca.2022.07.036. Epub 2022 Sep 17. PMID: 36126477.","DOI":"10.1016\/j.ejca.2022.07.036"},{"key":"10.1016\/j.ctrv.2026.103136_b0290","doi-asserted-by":"crossref","unstructured":"van 't Veer LJ, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Van de Velde CJH, Kleijn M, Dreezen C, Menicucci AR, Audeh W, Liefers GJ. Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 4;7(11):e2447530. doi: 10.1001\/jamanetworkopen.2024.47530. PMID: 39602119.","DOI":"10.1001\/jamanetworkopen.2024.47530"},{"key":"10.1016\/j.ctrv.2026.103136_b0295","doi-asserted-by":"crossref","unstructured":"Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093\/jnci\/djx134. PMID: 28922787.","DOI":"10.1093\/jnci\/djx134"},{"key":"10.1016\/j.ctrv.2026.103136_b0300","doi-asserted-by":"crossref","unstructured":"Haan JC, Bhaskaran R, Ellappalayam A, Bijl Y, Griffioen CJ, Lujinovic E, Audeh WM, Penault-Llorca F, Mittempergher L, Glas AM. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients. Genes Chromosomes Cancer. 2022 Mar;61(3):148-160. doi: 10.1002\/gcc.23014. Epub 2021 Dec 11. PMID: 34841595; PMCID: PMC9299843.","DOI":"10.1002\/gcc.23014"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-020-6534-z","article-title":"MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial","volume":"20","author":"Soliman","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103136_b0310","doi-asserted-by":"crossref","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200\/JCO.2008.18.1370. Epub 2009 Feb 9. PMID: 19204204; PMCID: PMC2667820.","DOI":"10.1200\/JCO.2008.18.1370"},{"key":"10.1016\/j.ctrv.2026.103136_b0315","doi-asserted-by":"crossref","unstructured":"Prat A, Galv\u00e1n P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, \u00c1lvarez M, D\u00edaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ram\u00f3n Y Cajal S, Peg V, Alba E. Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158\/1078-0432.CCR-15-0630. Epub 2015 Jul 7. PMID: 26152740.","DOI":"10.1158\/1078-0432.CCR-15-0630"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"22","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.ctrv.2026.103136_b0325","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2017.01.017","article-title":"Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)","volume":"75","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103136_b0330","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0335","doi-asserted-by":"crossref","unstructured":"Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093\/annonc\/mdt494. Epub 2013 Dec 16. PMID: 24347518.","DOI":"10.1093\/annonc\/mdt494"},{"key":"10.1016\/j.ctrv.2026.103136_b0340","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010 Nov 1;16(21):5222-32. doi: 10.1158\/1078-0432.CCR-10-1282. Epub 2010 Sep 13. PMID: 20837693; PMCID: PMC2970720.","DOI":"10.1158\/1078-0432.CCR-10-1282"},{"key":"10.1016\/j.ctrv.2026.103136_b0345","doi-asserted-by":"crossref","unstructured":"Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012 Aug 15;18(16):4465-72. doi: 10.1158\/1078-0432.CCR-12-0286. Epub 2012 Jun 18. PMID: 22711706; PMCID: PMC3743663.","DOI":"10.1158\/1078-0432.CCR-12-0286"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0350","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","article-title":"PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer","volume":"36","author":"L\u00e6nkholm","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0355","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","article-title":"Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up","volume":"19","author":"Ohnstad","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0360","doi-asserted-by":"crossref","unstructured":"Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016;2:15023\u2013. doi: 10.1038\/npjbcancer.2015.23. Epub 2016 Jan 6. PMID: 28691057; PMCID: PMC5501351.","DOI":"10.1038\/npjbcancer.2015.23"},{"key":"10.1016\/j.ctrv.2026.103136_b0365","doi-asserted-by":"crossref","unstructured":"Stein RC, Makris A, Hughes-Davies L, Macpherson IR, Hall PS, Cameron DA, Earl HM, Pinder SE, Poole CJ, Rea DW, McIntosh S, Harmer V, Morgan A, Rooshenas L, Conefrey C, Donovan JL, Hulme C, McCabe C, Stallard N, Campbell A, Higgins H, Bartlett JMS, Marshall A, Dunn JA. OPTIMA: A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-06-01.","DOI":"10.1158\/1538-7445.SABCS17-OT1-06-01"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103136_b0370","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2016.0922","article-title":"Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib","volume":"2","author":"Prat","year":"2016","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103136_b0375","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12916-015-0540-z","article-title":"Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy","volume":"18","author":"Prat","year":"2015","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103136_b0380","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-018-5020-7","article-title":"PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer","volume":"173","author":"Ohara","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103136_b0385","doi-asserted-by":"crossref","unstructured":"Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-M\u00f8ller S, Olsson P, Heie A, Manns\u00e5ker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, R\u00f8e OD, Geitvik GA, Halset EH, Rypdal MC, Langer\u00f8d A, L\u00f8mo J, Garred \u00d8, Porojnicu A, Engebraaten O, Geisler J, Lyngra M, Hansen MH, S\u00f8iland H, Nakken T, Asphaug L, Kristensen V, S\u00f8rlie T, Nyg\u00e5rd JF, Kiserud CE, Reinertsen KV, Russnes HG, Naume B. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1). ESMO Open. 2024 Jun;9(6):103475. doi: 10.1016\/j.esmoop.2024.103475. Epub 2024 Jun 4. PMID: 38838499; PMCID: PMC11190479.","DOI":"10.1016\/j.esmoop.2024.103475"},{"key":"10.1016\/j.ctrv.2026.103136_b0390","doi-asserted-by":"crossref","unstructured":"Corti C, Chu X, Exman P, Kline DM, Priedigkeit NM, Mayer EL, Waks AG, Hughes ME, Abravanel DL, Giordano A, Curigliano G, Lin NU, King TA, Jeselsohn RM, Manning DK, Dillon DA, Mittendorf EA, Tayob N, Tolaney SM. Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive\/HER2-negative breast cancer: a single-center prospective observational study. ESMO Open. 2025 Aug;10(8):105521. doi: 10.1016\/j.esmoop.2025.105521. Epub 2025 Jul 25. PMID: 40714511; PMCID: PMC12314373.","DOI":"10.1016\/j.esmoop.2025.105521"},{"key":"10.1016\/j.ctrv.2026.103136_b0395","doi-asserted-by":"crossref","unstructured":"Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, M\u00fcller V, J\u00e4nicke F, Schmidt M, K\u00f6lbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158\/1078-0432.CCR-11-0926. Epub 2011 Aug 1. PMID: 21807638.","DOI":"10.1158\/1078-0432.CCR-11-0926"},{"key":"10.1016\/j.ctrv.2026.103136_b0400","doi-asserted-by":"crossref","unstructured":"Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093\/jnci\/djp335. Epub 2009 Oct 8. PMID: 19815849; PMCID: PMC2782246.","DOI":"10.1093\/jnci\/djp335"},{"key":"10.1016\/j.ctrv.2026.103136_b0405","doi-asserted-by":"crossref","unstructured":"Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016 Jul 10;108(11):djw149. doi: 10.1093\/jnci\/djw149. PMID: 27400969; PMCID: PMC5241904.","DOI":"10.1093\/jnci\/djw149"},{"key":"10.1016\/j.ctrv.2026.103136_b0410","doi-asserted-by":"crossref","unstructured":"Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093\/annonc\/mds334. Epub 2012 Oct 3. PMID: 23035151; PMCID: PMC3574544.","DOI":"10.1093\/annonc\/mds334"},{"key":"10.1016\/j.ctrv.2026.103136_b0415","doi-asserted-by":"crossref","unstructured":"Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients. Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038\/bjc.2013.671. Epub 2013 Oct 24. PMID: 24157828; PMCID: PMC3859949.","DOI":"10.1038\/bjc.2013.671"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103136_b0420","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/1078-0432.CCR-19-0376","article-title":"Prediction of distant recurrence using endopredict among women with ER+, HER2- node-positive and node-negative breast cancer treated with endocrine therapy only","volume":"25","author":"Filipits","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0425","article-title":"Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charit\u00e9 registry","author":"Wolfgang","year":"2022","journal-title":"SABCS"},{"key":"10.1016\/j.ctrv.2026.103136_b0430","article-title":"Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer","author":"Klein","year":"2022","journal-title":"SABCS"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103136_b0435","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr3642","article-title":"Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+\/HER2- breast cancer patients: results from the GEICAM 9906 trial","volume":"16","author":"Martin","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0440","doi-asserted-by":"crossref","unstructured":"Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer. 2015 Apr 14;112(8):1405-10. doi: 10.1038\/bjc.2015.98. Epub 2015 Mar 24. PMID: 25867274; PMCID: PMC4402462.","DOI":"10.1038\/bjc.2015.98"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103136_b0445","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-20-0260","article-title":"Prognostic value of endopredict in women with hormone receptor-positive, HER2-negative invasive lobular breast cancer","volume":"26","author":"Sestak","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103136_b0450","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1158\/1078-0432.CCR-22-0619","article-title":"Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-negative Primary Breast Cancer","volume":"28","author":"Constantinidou","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0455","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2020.04.020","volume":"134","author":"Dubsky","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103136_b0460","doi-asserted-by":"crossref","unstructured":"Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. ESMO Open. 2024 May;9(5):103443. doi: 10.1016\/j.esmoop.2024.103443. Epub 2024 Apr 30. PMID: 38692082; PMCID: PMC11070798.","DOI":"10.1016\/j.esmoop.2024.103443"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0465","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2014.09.014","article-title":"EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer","volume":"355","author":"Bertucci","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2026.103136_b0470","doi-asserted-by":"crossref","unstructured":"Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value. Endocr Relat Cancer. 2018 Feb;25(2):123-130. doi: 10.1530\/ERC-17-0396. Epub 2017 Nov 20. PMID: 29158285; PMCID: PMC5763422.","DOI":"10.1530\/ERC-17-0396"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103136_b0475","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ccr.2004.05.015","article-title":"A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen","volume":"5","author":"Ma","year":"2004","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103136_b0480","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-07-5026","article-title":"A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer","volume":"14","author":"Ma","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103136_b0485","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2006.06.6944","article-title":"The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer","volume":"24","author":"Ma","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7 Pt 1","key":"10.1016\/j.ctrv.2026.103136_b0490","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-05-1263","article-title":"A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen","volume":"12","author":"Goetz","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103136_b0495","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-007-9541-8","article-title":"Exploring the two-gene ratio in breast cancer\u2013independent roles for HOXB13 and IL17BR in prediction of clinical outcome","volume":"107","author":"Jerevall","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103136_b0500","doi-asserted-by":"crossref","unstructured":"Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskj\u00f6ld B, St\u00e5l O. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res. 2010;12(4):R53. doi: 10.1186\/bcr2612. Epub 2010 Jul 22. PMID: 20649975; PMCID: PMC2949642.","DOI":"10.1186\/bcr2612"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103136_b0505","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/bcr3038","article-title":"Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer","volume":"13","author":"Jankowitz","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103136_b0510","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0515","doi-asserted-by":"crossref","unstructured":"Jerevall PL, Ma XJ, Li H, Salunga R, Kesty NC, Erlander MG, Sgroi DC, Holmlund B, Skoog L, Fornander T, Nordenskj\u00f6ld B, St\u00e5l O. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011 May 24;104(11):1762-9. doi: 10.1038\/bjc.2011.145. Epub 2011 May 10. PMID: 21559019; PMCID: PMC3111159.","DOI":"10.1038\/bjc.2011.145"},{"key":"10.1016\/j.ctrv.2026.103136_b0520","doi-asserted-by":"crossref","unstructured":"Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016\/S1470-2045(13)70387-5. Epub 2013 Sep 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016\/S1470-2045(18)30214-6. PMID: 24035531; PMCID: PMC3918681.","DOI":"10.1016\/S1470-2045(13)70387-5"},{"key":"10.1016\/j.ctrv.2026.103136_b0525","doi-asserted-by":"crossref","unstructured":"Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13\/IL17BR biomarker. J Natl Cancer Inst. 2013 Jul 17;105(14):1036-42. doi: 10.1093\/jnci\/djt146. Epub 2013 Jun 28. PMID: 23812955; PMCID: PMC3888138.","DOI":"10.1093\/jnci\/djt146"},{"key":"10.1016\/j.ctrv.2026.103136_b0530","doi-asserted-by":"crossref","unstructured":"Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186\/s13058-015-0660-6. PMID: 26728744; PMCID: PMC4700696.","DOI":"10.1186\/s13058-015-0660-6"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103136_b0535","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1158\/1078-0432.CCR-17-1688","article-title":"A novel breast cancer index for prediction of distant recurrence in HR+ early-stage breast cancer with one to three positive nodes","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103136_b0540","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-to offer more? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0545","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-20-2737","article-title":"Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy","volume":"27","author":"Noordhoek","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103136_b0550","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-23-1977","article-title":"Breast cancer index and prediction of extended aromatase inhibitor therapy benefit in hormone receptor-positive breast cancer from the NRG oncology\/NSABP B-42 trial","volume":"30","author":"Mamounas","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103136_b0555","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clbc.2020.01.001","article-title":"Case-based review and clinical guidance on the use of genomic assays for early-stage breast cancer: breast cancer therapy expert group (BCTEG)","volume":"20","author":"Kittaneh","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103136_b0560","doi-asserted-by":"crossref","unstructured":"Nguyen Van Long F, Poirier B, Desbiens C, Perron M, Paquet C, Ouellet C, Diorio C, Lemieux J, Nabi H. First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers? Cancer Treat Rev. 2025 Apr;135:102909. doi: 10.1016\/j.ctrv.2025.102909. Epub 2025 Feb 27. Erratum in: Cancer Treat Rev. 2026 Feb;143:103088. doi: 10.1016\/j.ctrv.2026.103088. PMID: 40054315.","DOI":"10.1016\/j.ctrv.2026.103088"},{"key":"10.1016\/j.ctrv.2026.103136_b0565","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038\/nature11412. Epub 2012 Sep 23. PMID: 23000897; PMCID: PMC3465532.","DOI":"10.1038\/nature11412"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103136_b0570","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41576-021-00338-8","article-title":"Clinical cancer genomic profiling","volume":"22","author":"Chakravarty","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ctrv.2026.103136_b0575","doi-asserted-by":"crossref","unstructured":"Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 Jun 1;40(16):1816-1837. doi: 10.1200\/JCO.22.00069. Epub 2022 Apr 19. Erratum in: J Clin Oncol. 2022 Aug 1;40(22):2514. doi: 10.1200\/JCO.22.01388. PMID: 35439025.","DOI":"10.1200\/JCO.22.00069"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103136_b0580","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamaoncol.2017.5524","article-title":"Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial","volume":"4","author":"Sestak","year":"2018","journal-title":"JAMA Oncol"},{"issue":"28","key":"10.1016\/j.ctrv.2026.103136_b0585","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0590","doi-asserted-by":"crossref","unstructured":"Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093\/jnci\/djn309. Epub 2008 Sep 23. PMID: 18812550; PMCID: PMC2556704.","DOI":"10.1093\/jnci\/djn309"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103136_b0595","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103136_b0600","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.3390\/cancers14225668","article-title":"Signatures of breast cancer progression in the blood: What could be learned from circulating tumor cell transcriptomes","volume":"14","author":"Fina","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103136_b0605","doi-asserted-by":"crossref","unstructured":"Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19;374(9707):2055-2063. doi: 10.1016\/S0140-6736(09)61523-3. Epub 2009 Dec 10. PMID: 20004966; PMCID: PMC3140679.","DOI":"10.1016\/S0140-6736(09)61523-3"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103136_b0610","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0615","doi-asserted-by":"crossref","unstructured":"Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge; Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. Cancer Res 1 March 2023; 83 (5_Supplement): GS1\u201305. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-GS1-05.","DOI":"10.1158\/1538-7445.SABCS22-GS1-05"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103136_b0620","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.21.02019","article-title":"Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial","volume":"40","author":"Lopes Cardozo","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103136_b0625","doi-asserted-by":"crossref","unstructured":"Robert Stein; Andreas Makris; Iain Macpherson; Luke Hughes-Davies; Andrea Marshall; Georgina Dotchin; David A. Cameron; Belinda E. Kiely; Caroline Wilson; Anne Armstrong; Helena M. Earl; Christopher J. Poole; Janice Tsang; Bj\u00f8rn Naume; Daniel Rea; Hege Ohnstad; Peter S. Hall; Stuart A. McIntosh; Bethany Shinkins; Christopher McCabe; Adrienne Morgan; John MS Bartlett; Janet A. Dunn. Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer. Cancer Res (2023) 83 (5_Supplement): OT3-32-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-OT3-32-01.","DOI":"10.1158\/1538-7445.SABCS22-OT3-32-01"},{"issue":"4_Supplement","key":"10.1016\/j.ctrv.2026.103136_b0630","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-OT2-04-03","article-title":"Abstract OT2-04-03: Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal a breast cancer","volume":"79","author":"Chua","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103136_b0635","doi-asserted-by":"crossref","unstructured":"J. Lehmann-Che J. Wong L. Lacroix M. Lacroix-Triki L. Arnould P.J. Lamy V. Quillien F. Godey I. Soubeyran G. MacGrogan J. Haudebourg M. Dup\u00e9 M-F. Heymann D. Raoux S. Manz A. Tallet N. Padilla L. Dainese L. Karayan-Tapon F. Penault-Llorca. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers. Annals of Oncology 32S430. DOI: 10.1016\/j.annonc.2021.08.440.","DOI":"10.1016\/j.annonc.2021.08.440"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103136_b0640","article-title":"Assessment of adjuvant endocrine therapy with ovarian function suppression by breast cancer index","volume":"8","author":"O'Regan","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:51:27Z","timestamp":1778745087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":128,"alternative-id":["S0305737226000502"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103136","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multigene assays in early breast cancer: Current evidence, limits and future directions","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103136"}}